What is the importance and potential of comprehensive genomic profiling in lung cancer?
The benefit of a comprehensive study of the status of genes, by the way, not only genes, but also some protein factors, is at the moment the basis for the choice of treatment method. This applies to patients with advanced lung cancer, as well as already some patients who are undergoing radical treatment. It is about postoperative adjuvant treatment, also about preoperative treatment, or perioperative treatment. The options related to the need for knowledge of characteristics, whether genetic or molecular, are also expanding more and more. This is of primary importance at the moment.
What does it look like at the moment?
At the moment, availability is certainly an issue. Laboratories or facilities that perform so-called multiscale genetic testing, that is, covering a very wide range of genetic aberrations, are a bit too few. There is also the problem of the rather complicated system of financing genetic testing. Certainly, there is also the problem of insufficient awareness of the users, i.e. doctors who provide anticancer treatment. All this creates such a situation that tests are unfortunately performed too little, which also results in underutilization of the options that are in the drug program.
